Advertisement

Topics

Avacta Group Plc making 'excellent progress' on lead programmes

11:22 EDT 16 Apr 2018 | Proactive Investors

Alastair Smith, chief executive of Avacta Group Plc (LON:AVCT), tells Proactive Investors their lead PD-L1 programme remains on track to deliver key pre-clinical milestones this year.

Smith says they're also making “excellent progress” with a second immuno-oncology research project, a LAG3 blockade, which can be combined with PD-L1 for improved efficacy.

Avacta, in its half-year results update, said its discovery programme continued to deliver a pipeline of binders to other important immuno-oncology targets for future partnering or development.

Original Article: Avacta Group Plc making 'excellent progress' on lead programmes

NEXT ARTICLE

More From BioPortfolio on "Avacta Group Plc making 'excellent progress' on lead programmes"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...